F&P myAIRVO™ 2 
Humidified High Flow Therapy 

 

World leading respiratory technology

 

Enquire about evaluating myAIRVO

 

Facebook LinkedIn YouTube Twitter

Humidified High Flow Therapy


Humidified high flow therapy with myAIRVO 2 delivers warmed and humidified air/oxygen mixtures to the patient through a comfortable interface. It is designed for use in the home and long-term care facilities.

 

NHF reduces exacerbations compared to usual care in COPD patients with chronic hypoxemic respiratory failure

 

~ Storgaard et al 2018



NHF improves quality
of life compared to usual care in patients with stable COPD

 

 

~ Nagata et al 2018
~ Storgaard et al 2018



NHF reduces PCO2 compared to usual care in patients with stable COPD
 

 

~ Nagata et al 2018
~ Storgaard et al 2018

How does Optiflow work?



The mechanisms of action

With NHF therapy, you can independently titrate flow and FiO2 to match your patient’s needs. The mechanisms of action differ from those of conventional therapies, as do the resulting physiological effects and clinical outcomes.

Mechanisms of NHF therapy are:​ 

  • Airway hydration
  • Respiratory support (through the reduction of dead space
  • and delivery of a dynamic positive airway pressure)
  • Patient comfort
  • Supplemental oxygen (if required)

Note: the above mechanisms of action for nasal high flow apply to delivery through an Optiflow nasal cannula interface. The mechanisms of action differ when high flow is delivered through a tracheostomy or mask interface adapter
 

Optiflow High Flow airway hydration mechanism overview

Airway hydration
 
Optiflow High Flow deadspace mechanism overview
Respiratory support
 
Optiflow High Flow pressure mechanism overview
Dynamic Positive Airway Pressure
 

Usage


There is an increasing body of clinical literature which may provide guidance on the day-to-day application of humidified high flow.
 

Elderly lady receiving myAIRVO Nasal High Flow therapy

Nasal High Flow and COPD focused webinar


Learn more about myAIRVO system and Nasal High Flow.

Associate Professor Ulla Møller Weinreich speaks about her research "Humidified High Flow therapy for chronic COPD patients" in this Nasal High Flow and COPD focused webinar.